Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Details) - Schedule of segment reporting information, by segment

v3.8.0.1
Segment reporting (Details) - Schedule of segment reporting information, by segment - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jan. 31, 2018
Jan. 31, 2017
Jan. 31, 2018
Jan. 31, 2017
Segment Reporting Information [Line Items]        
Clinical laboratory services $ 19,530 $ 18,837 $ 39,864 $ 37,395
Product revenues 7,122 6,983 14,203 14,409
Royalty and license fee income 300 440 561 740
Total revenues 26,952 26,260 54,628 52,544
Cost of clinical laboratory services 11,730 11,052 23,772 21,948
Cost of product revenues 3,877 3,520 7,266 6,829
Research and development 812 483 1,559 1,305
Selling, general and administrative 11,070 11,218 21,961 22,712
Provision for uncollectible accounts receivable 779 679 1,593 1,348
Legal fee expense 1,700 370 2,131 742
Operating income (loss) (3,016) (1,062) (3,654) (2,340)
Other 33 24 69 143
Foreign exchange gain (loss) 800 (94) 605 (455)
Share-based compensation 208 241 413 392
Selling, General and Administrative Expenses [Member]        
Segment Reporting Information [Line Items]        
Share-based compensation 208 240 413 389
Cost of Clinical Laboratory Services [Member]        
Segment Reporting Information [Line Items]        
Share-based compensation   1   3
Clinical Labs [Member]        
Segment Reporting Information [Line Items]        
Clinical laboratory services 19,530 18,837 39,864 37,395
Total revenues 19,530 18,837 39,864 37,395
Cost of clinical laboratory services 11,730 11,052 23,772 21,948
Selling, general and administrative 6,107 5,897 12,202 11,849
Provision for uncollectible accounts receivable 800 594 1,600 1,260
Legal fee expense 8 49 21 101
Total operating costs and expenses 18,645 17,592 37,595 35,158
Operating income (loss) 885 1,245 2,269 2,237
Interest (23) (28) (48) (57)
Other 3 17 17 119
Income (loss) before income taxes 865 1,234 2,238 2,299
Depreciation and amortization included above 413 394 817 795
Capital expenditures 576 175 994 587
Clinical Labs [Member] | Selling, General and Administrative Expenses [Member]        
Segment Reporting Information [Line Items]        
Share-based compensation 28 23 60 40
Clinical Labs [Member] | Total [Member]        
Segment Reporting Information [Line Items]        
Share-based compensation 28 24 60 43
Clinical Labs [Member] | Cost of Clinical Laboratory Services [Member]        
Segment Reporting Information [Line Items]        
Share-based compensation   1   3
Life Sciences [Member]        
Segment Reporting Information [Line Items]        
Product revenues 7,122 6,983 14,203 14,409
Royalty and license fee income 300 440 561 740
Total revenues 7,422 7,423 14,764 15,149
Cost of product revenues 3,877 3,520 7,266 6,829
Research and development 591 516 1,114 1,143
Selling, general and administrative 2,899 2,905 5,513 5,851
Provision for uncollectible accounts receivable (21) 85 (7) 88
Legal fee expense 25 16 28 28
Total operating costs and expenses 7,371 7,042 13,914 13,939
Operating income (loss) 51 381 850 1,210
Interest 11 12 23 22
Other 1   8  
Foreign exchange gain (loss) 800 (94) 605 (455)
Income (loss) before income taxes 863 299 1,486 777
Depreciation and amortization included above 355 501 681 1,009
Capital expenditures 28   72 102
Life Sciences [Member] | Selling, General and Administrative Expenses [Member]        
Segment Reporting Information [Line Items]        
Share-based compensation 21 15 44 26
Life Sciences [Member] | Total [Member]        
Segment Reporting Information [Line Items]        
Share-based compensation 21 15 44 26
Therapeutics [Member]        
Segment Reporting Information [Line Items]        
Research and development 221 (33) 445 162
Total operating costs and expenses 221 (33) 445 162
Operating income (loss) (221) 33 (445) (162)
Income (loss) before income taxes (221) 33 (445) (162)
Other Segments [Member]        
Segment Reporting Information [Line Items]        
Selling, general and administrative 2,064 2,416 4,246 5,012
Legal fee expense 1,667 305 2,082 613
Total operating costs and expenses 3,731 2,721 6,328 5,625
Operating income (loss) (3,731) (2,721) (6,328) (5,625)
Interest 197 95 367 160
Other 29 7 44 24
Income (loss) before income taxes (3,505) (2,619) (5,917) (5,441)
Depreciation and amortization included above 18 20 37 38
Other Segments [Member] | Selling, General and Administrative Expenses [Member]        
Segment Reporting Information [Line Items]        
Share-based compensation 159 202 309 323
Other Segments [Member] | Total [Member]        
Segment Reporting Information [Line Items]        
Share-based compensation 159 202 309 323
Consolidated [Member]        
Segment Reporting Information [Line Items]        
Clinical laboratory services 19,530 18,837 39,864 37,395
Product revenues 7,122 6,983 14,203 14,409
Royalty and license fee income 300 440 561 740
Total revenues 26,952 26,260 54,628 52,544
Cost of clinical laboratory services 11,730 11,052 23,772 21,948
Cost of product revenues 3,877 3,520 7,266 6,829
Research and development 812 483 1,559 1,305
Selling, general and administrative 11,070 11,218 21,961 22,712
Provision for uncollectible accounts receivable 779 679 1,593 1,348
Legal fee expense 1,700 370 2,131 742
Total operating costs and expenses 29,968 27,322 58,282 54,884
Operating income (loss) (3,016) (1,062) (3,654) (2,340)
Interest 185 79 342 125
Other 33 24 69 143
Foreign exchange gain (loss) 800 (94) 605 (455)
Income (loss) before income taxes (1,998) (1,053) (2,638) (2,527)
Depreciation and amortization included above 786 915 1,535 1,842
Capital expenditures 604 175 1,066 689
Consolidated [Member] | Selling, General and Administrative Expenses [Member]        
Segment Reporting Information [Line Items]        
Share-based compensation 208 240 413 389
Consolidated [Member] | Total [Member]        
Segment Reporting Information [Line Items]        
Share-based compensation $ 208 241 $ 413 392
Consolidated [Member] | Cost of Clinical Laboratory Services [Member]        
Segment Reporting Information [Line Items]        
Share-based compensation   $ 1   $ 3